<!doctype html>
<html lang="en"><head>
<meta charset="utf-8"/><meta name="viewport" content="width=device-width,initial-scale=1"/>
<link rel="stylesheet" href="/Newsletter/style.css"/>
<title>How the Narrative for Regeneron Has Shifted with Pipeline Wins and Analyst Optimism â€” Newsletter</title>
</head><body>
<div class="container">
  <div class="header">
    <h1 style="margin:0;font-size:28px">Newsletter</h1>
    <a class="btn" href="/Newsletter/">Home</a>
  </div>
  <div class="card">
    <h2 style="margin-top:0">How the Narrative for Regeneron Has Shifted with Pipeline Wins and Analyst Optimism</h2>
    <div class="badge">2025-09-20T12:34:17+00:00</div>
    <ul>
      <li>Regeneron completed a $3 billion share repurchase, buying back 4.1% of its outstanding shares under a program announced in May 2024.</li>
<li>The Consensus Revenue Growth forecasts for Regeneron Pharmaceuticals remained effectively unchanged, at 5.4% per annum.</li>
<li>One firm raised its target from $700 to $750 following the latest earnings beat.</li>
<li>The Consensus Analyst Price Target remained effectively unchanged, moving only marginally from $716.87 to $722.20.</li>
<li>The treatment achieved a greater than 90% reduction in new HO lesions, which prompted the Data Monitoring Committee to recommend the transition of placebo patients to garetosmab.</li>
<li>Regeneron Pharmaceuticals recently saw its consensus analyst price target move only slightly, shifting from $716.87 to $722.20.</li>
<li>NasdaqGS:REGN Community Fair Values as at Sep 2025 Regeneron reported positive Phase 3 results for garetosmab in fibrodysplasia ossificans progressiva.</li>
    </ul>
    <p>
      <a class="btn" href="https://x.com/intent/tweet?text=How%20the%20Narrative%20for%20Regeneron%20Has%20Shifted%20with%20Pipeline%20Wins%20and%20Analyst%20Optimism%0A%E2%80%A2%20Regeneron%20completed%20a%20%243%20billion%20share%20repurchase%2C%20buying%20back%204.1%25%20of%20its%20outstanding%20shares%20under%20a%20program%20announced%20in%20May%202024.%0A%E2%80%A2%20The%20Consensus%20Revenue%20Growth%20forecasts%20for%20Regeneron%20Pharmaceuticals%20remained%20effectively%20unchanged%2C%20at%205.4%25%20per%20annum.%0A%E2%80%A2%20One%20firm%20raised%20its%20target%20from%20%24700%20to%20%24750%20following%20the%20latest%20earnings%20beat.%0A%E2%80%A2%20The%20Consensus%20Analyst%20Price%20Target%20remained%20effectively%20unchanged%2C%20moving%20only%20marginally%20from%20%24716.87%20to%20%24722.20.%0A%E2%80%A2%20The%20treatment%20achieved%20a%20greater%20than%2090%25%20reduction%20in%20new%20HO%20lesions%2C%20which%20prompted%20the%20Data%20Monitoring%20Committee%20to%20recommend%20the%20transition%20of%20placebo%20patients%20to%20garetosmab.%0A%E2%80%A2%20Regeneron%20Pharmaceuticals%20recently%20saw%20its%20consensus%20analyst%20price%20target%20move%20only%20slightly%2C%20shifting%20from%20%24716.87%20to%20%24722.20.%0A%E2%80%A2%20NasdaqGS%3AREGN%20Community%20Fair%20Values%20as%20at%20Sep%202025%20Regeneron%20reported%20positive%20Phase%203%20results%20for%20garetosmab%20in%20fibrodysplasia%20ossificans%20progressiva.&url=https%3A%2F%2Fsuavir600.github.io%2FNewsletter%2Farticles%2Fhow-the-narrative-for-regeneron-has-shifted-with-pipeline-wins-and-analyst-optim%2F" target="_blank" rel="noopener">Tweet bullets</a>
      &nbsp;&nbsp;
      <a class="btn" href="https://finance.yahoo.com/news/narrative-regeneron-shifted-pipeline-wins-123417487.html" target="_blank" rel="noopener nofollow">finance.yahoo.com</a>
    </p>
  </div>
  <div class="footer">Built from digest_5bullets.md</div>
</div>
</body></html>